Novartis strikes up to $2 billion deal for Excellergy

Anabelle Colaco
30 Mar 2026, 01:46 GMT+10

Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2 billion, marking its second major acquisition in recent weeks
The company said on March 27 that the agreement includes upfront and milestone payments that could total up to $2 billion
Novartis said the acquisition will strengthen its presence in immunology, particularly in treating food allergies

BASEL, Switzerland: Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2 billion, marking its second major acquisition in recent weeks.

The company said on March 27 that the agreement includes upfront and milestone payments that could total up to $2 billion. The deal is expected to close in the second half of 2026, subject to regulatory approvals and other customary conditions.

Novartis said the acquisition will strengthen its presence in immunology, particularly in treating food allergies.

Excellergy's lead drug candidate, Exl-111, is being developed to provide earlier relief from allergy symptoms, the company said.

The move follows another recent acquisition announcement by Novartis, which last week said it would buy a breast cancer drug candidate from U.S. biotech firm Synnovation Therapeutics for up to $3 billion.

The latest deal is part of a broader strategy to expand Novartis' pipeline through targeted acquisitions and investments in high-growth therapeutic areas.

In April last year, Novartis outlined plans to invest $23 billion in the United States over five years to build and expand research and manufacturing capabilities.

The company has since begun construction on research and development and manufacturing facilities across four U.S. states, including California. It has expanded its radioligand therapy operations in Indiana and New Jersey.

The Excellergy acquisition is expected to complement those efforts by adding new allergy-treatment capabilities to Novartis' portfolio.

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Beijing Bulletin.

More Information

Technology

Section

$6 million verdict against Meta, Google sets tone for future lawsuits

LOS ANGELES, California: In a US$6 million verdict that will serve ‌as a bellwether for numerous similar cases, Meta and Alphabet's...

Jury finds Meta liable, orders $375 million penalty in lawsuit

SANTA FE, New Mexico: A New Mexico jury has ordered Meta Platforms to pay US$375 million in civil penalties after finding the company...

After app exposes French ship’s location, government takes action

PARIS, France: After a naval officer's use of the Strava exercise app inadvertently allowed journalists to geolocate the French aircraft...

Digital cooperation key to global development goals: GIWEH

Geneva [Switzerland], March 26 (ANI): At the 61st session of the United Nations Human Rights Council in Geneva, the Global Institute...

Major DDoS cyberattack disrupts Uyghur Post, incident reported to US authorities

Washington DC [US], March 26 (ANI): A significant cyberattack aimed at Uyghur Post has been detected and reported to U.S. authorities,...

The Rise of Digital Industries in Bulgarias Economy

Bulgaria's digital economy is starting to outgrow its old label. The country was discussed mainly as a lower-cost base for outsourced...

Business

Section